Cubist Pharmaceuticals Inc., of Lexington, Mass., said 36.1 million shares of Exton, Pa.-based Adolor Corp. were initially tendered under Cubist's $415 million offer to acquire the biotech. That figure represents about 75 percent of Adolor's shares, and Cubist commenced a subsequent offering period that is scheduled to expire Dec. 9.